Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization

Obesity is a multifactorial, complex disease that is driven by genetic, biological, environmental, and behavioral factors. In this review, we explain the key contributors to obesity, limitations in current definitions, its relationship with cardiometabolic health, and recent advancements in treatment. Obesity is characterized by the presence of excess and dysfunctional adipose tissue, driven by chronic inflammation and maladaptive energy homeostasis. Although body mass index (BMI) has historically been used to diagnose obesity, BMI provides a limited evaluation of individual patients because it fails to specifically quantify adiposity, which is the primary determinant of metabolic impact in these patients. There is an ongoing and necessary shift in treating obesity with a weight-inclusive approach that aims to address obesity upstream and prevent downstream cardiometabolic health complications. This approach is being supported by various treatment options, notably glucagon-like peptide-1 receptor agonists like semaglutide and tirzepatide, that also have promising effects on cardiovascular, renal, and liver health. Advances in precision medicine, gut microbiome research, and Multi-target therapies support personalized therapeutic approach. Despite these developments, less than 25% of individuals living with obesity are receiving evidence-based treatment. There is an urgent need to improve health care delivery to patients with obesity through timely, affordable, and multimodal treatments that promote sustainable and sustained weight loss. Increasing board certification of practicing physicians through the American Board of Obesity Medicine will be critical to improving access and quality of care.

• Publication year

  2025

• Venue

  Advances in Therapy

• Publication date

  2025-09-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12325-025-03352-yPMID 40911213PMCID 12579698
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Definition and diagnostic criteria of clinical obesity.

  2025cited by this paper
• Dozens of new obesity drugs are coming: these are the ones to watch

  2025cited by this paper
• Long-Term Outcomes in Sleeve Gastrectomy versus Roux-en-Y Gastric Bypass: A Systematic Review and Meta-Analysis of Randomized Trials

  2025cited by this paper
• FGF-based drug discovery: advances and challenges

  2025cited by this paper
• Obesity-Related Glomerulosclerosis—How Adiposity Damages the Kidneys

  2025cited by this paper
• The (dys)regulation of energy storage in obesity.

  2025cited by this paper
• The association between food insecurity and obesity, a body shape index and body roundness index among US adults

  2024cited by this paper
• Could the Body Roundness Index One Day Replace the BMI?

  2024cited by this paper
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

  2024cited by this paper
• Factors associated with receiving an obesity diagnosis and obesity-related treatment for patients with obesity class II and III within a single integrated health system

  2024influential reference
• Obesity: exploring its connection to brain function through genetic and genomic perspectives

  2024cited by this paper
• The POSE-2 Procedure for People with Obesity: A Safe and Effective Treatment Option

  2024cited by this paper
• The out‐of‐pocket cost of living with obesity: Results from a survey in Spain, South Korea, Brazil, India, Italy, and Japan

  2024cited by this paper
• Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023.

  2024influential reference
• Medications for Obesity: A Review.

  2024influential reference
• Phenotyping of Obesity Treatment Candidates: A Narrative Review

  2024cited by this paper
• Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

  2024cited by this paper
• Body Roundness Index and All-Cause Mortality Among US Adults

  2024cited by this paper
• Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

  2024cited by this paper
• Obesity

  2024cited by this paper
• Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions

  2024cited by this paper
• Impact of Body Mass Index on All-Cause Mortality in Adults: A Systematic Review and Meta-Analysis

  2024cited by this paper
• Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss

  2024influential reference
• Orally Ingested Self‐Powered Stimulators for Targeted Gut–Brain Axis Electrostimulation to Treat Obesity and Metabolic Disorders

  2024cited by this paper
• Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

  2024cited by this paper
• The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis

  2024cited by this paper
• GLP-1 Agonists for Obesity-A New Recipe for Success?

  2024cited by this paper
• Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.

  2024cited by this paper
• What is the pipeline for future medications for obesity?

  2024cited by this paper
• Prevention of cardiorenal complications in people with type 2 diabetes and obesity.

  2024cited by this paper
• Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels

  2024influential reference
• Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

  2024cited by this paper
• IFSO Bariatric Endoscopy Committee Evidence-Based Review and Position Statement on Endoscopic Sleeve Gastroplasty for Obesity Management

  2024cited by this paper
• Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists

  2024cited by this paper
• Advances in Endoscopic Bariatric and Metabolic Therapies.

  2024cited by this paper
• Rewriting cellular fate: epigenetic interventions in obesity and cellular programming

  2024cited by this paper
• Endobariatrics: a Still Underutilized Weight Loss Tool

  2023cited by this paper
• Long term outcomes of metabolic/bariatric surgery in adults

  2023influential reference
• 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2024.

  2023cited by this paper
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.

  2023cited by this paper
• Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice

  2023cited by this paper
• Obesity Management in Adults: A Review.

  2023cited by this paper
• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

  2023cited by this paper
• Changing the global obesity narrative to recognize and reduce weight stigma: A position statement from the World Obesity Federation

  2023cited by this paper
• Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

  2023influential reference
• Healthcare costs attributable to abnormal weight in China: evidence based on a longitudinal study

  2023cited by this paper
• Racial Disparities in Obesity‐Related Cardiovascular Mortality in the United States: Temporal Trends From 1999 to 2020

  2023cited by this paper
• Mechanisms of Action of Bariatric Surgery on Body Weight Regulation.

  2023cited by this paper
• Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor

  2023cited by this paper
• Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

  2023cited by this paper
• Fecal Microbiota Transplantation for Weight and Glycemic Control of Obesity as Well as the Associated Metabolic Diseases: Meta-Analysis and Comprehensive Assessment

  2023cited by this paper
• Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

  2023cited by this paper
• Social determinants of health, health disparities, and adiposity.

  2023cited by this paper
• Contemporary medical, device, and surgical therapies for obesity in adults.

  2023cited by this paper
• Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management

  2023cited by this paper
• Social determinants of health and obesity: Findings from a national study of US adults

  2022cited by this paper
• A review of current guidelines for the treatment of obesity.

  2022influential reference
• Identifying factors associated with central obesity in school students using artificial intelligence techniques

  2022cited by this paper
• Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

  2022cited by this paper
• Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

  2022cited by this paper
• The consequences of a weight-centric approach to healthcare: A case for a paradigm shift in how clinicians address body weight.

  2022cited by this paper
• Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial.

  2022cited by this paper
• Tirzepatide Once Weekly for the Treatment of Obesity.

  2022influential reference
• Diabetes and Kidney Disease

  2022cited by this paper
• Regulation of body weight: Lessons learned from bariatric surgery

  2022cited by this paper
• Changes in healthcare spending attributable to obesity and overweight: payer- and service-specific estimates

  2022cited by this paper
• Excess mortality associated with elevated body weight in the USA by state and demographic subgroup: A modelling study

  2022cited by this paper
• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

  2022cited by this paper
• GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions

  2022cited by this paper
• Social Determinants of Cardiovascular Disease

  2022cited by this paper
• Effect of glucagon‐like peptide‐1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta‐analysis of randomized control trials

  2022cited by this paper
• Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.

  2022cited by this paper
• Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

  2021cited by this paper
• β3-Adrenergic receptor downregulation leads to adipocyte catecholamine resistance in obesity

  2021cited by this paper
• Intragastric Balloon as Bridging Therapy Prior to Bariatric Surgery for Patients with Severe Obesity (BMI ≥ 50 kg/m2): a Systematic Review and Meta-analysis

  2021cited by this paper
• The genetics of obesity: from discovery to biology

  2021cited by this paper
• The Utility of Body Composition Assessment in Nutrition and Clinical Practice: An Overview of Current Methodology

  2021cited by this paper
• Differential associations of the built environment on weight gain by sex and race/ethnicity but not age

  2021cited by this paper
• Health policy and public health implications of obesity in China.

  2021cited by this paper
• International comparisons of weight stigma: addressing a void in the field

  2021cited by this paper
• Clinical management and treatment of obesity in China.

  2021cited by this paper
• Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

  2021cited by this paper
• Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

  2021cited by this paper
• Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease

  2021cited by this paper
• Once-Weekly Semaglutide in Adults with Overweight or Obesity.

  2021influential reference
• Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.

  2021cited by this paper
• Suture pattern does not influence outcomes of endoscopic sleeve gastroplasty in obese patients

  2020cited by this paper
• Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial

  2020cited by this paper
• Joint international consensus statement for ending stigma of obesity

  2020cited by this paper
• Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial

  2020cited by this paper
• Obesity Phenotypes, Diabetes, and Cardiovascular Diseases.

  2020cited by this paper
• A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

  2020cited by this paper
• Adipose Tissue Inflammation and Metabolic Dysfunction in Obesity.

  2020cited by this paper
• Contribution of adipogenesis to healthy adipose tissue expansion in obesity.

  2019cited by this paper
• The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action

  2019cited by this paper
• Why primary obesity is a disease?

  2019cited by this paper
• Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study

  2019cited by this paper
• The expression of genes in top obesity-associated loci is enriched in insula and substantia nigra brain regions involved in addiction and reward

  2019cited by this paper
• A Protocol to Deliver Intensive Behavioral Therapy (IBT) for Obesity in Primary Care Settings: The MODEL‐IBT Program

  2019cited by this paper
• Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.

  2018cited by this paper

• Obesity, women’s reproductive health, and demography. a contemporary perspective on the problem

  2025cites this paper